Cannabis and Cannabinoids (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (12/08/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information

Added Abrams as reference 2.

Human/Clinical Studies

Added text about a Cochrane meta-analysis of 23 randomized controlled trials that reviewed studies conducted between 1975 and 1991 that investigated dronabinol or nabilone, either as monotherapy or as an adjunct to the conventional dopamine antagonists that were the standard antiemetics at that time (cited Smith et al. as reference 26).

This summary is written and maintained by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Summary of the Evidence for Cannabis and Cannabinoids

Next section >
About This PDQ Summary